2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

Ashish R. Panchal; Katherine M. Berg; Peter J. Kudenchuk; Marina Del Rios; Karen G. Hirsch; Mark S. Link; Michael C. Kurz; Paul S. Chan; José G. Cabañas; Peter T. Morley; Mary Fran Hazinski; Michael W. Donnino

doi:10.1161/CIR.0000000000000613

2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

Ashish R. Panchal, Katherine M. Berg, Peter J. Kudenchuk, Marina Del Rios, Karen G. Hirsch, Mark S. Link, Michael C. Kurz, Paul S. Chan, José G. Cabañas, Peter T. Morley, Mary Fran Hazinski, Michael W. Donnino

Research output: Contribution to journal › Article › peer-review

135 Scopus citations

Abstract

Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.

Original language	English (US)
Pages (from-to)	e740-e749
Journal	Circulation
Volume	138
Issue number	23
DOIs	https://doi.org/10.1161/CIR.0000000000000613
State	Published - Dec 4 2018

Keywords

advanced cardiac life support, adult
AHA Scientific Statements
anti-arrhythmia agents
cardiopulmonary resuscitation
heart arrest
tachycardia, ventricular
ventricular fibrillation

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1161/CIR.0000000000000613

Fingerprint

Dive into the research topics of '2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care'. Together they form a unique fingerprint.

Cite this

Panchal, A. R., Berg, K. M., Kudenchuk, P. J., Del Rios, M., Hirsch, K. G., Link, M. S., Kurz, M. C., Chan, P. S., Cabañas, J. G., Morley, P. T., Hazinski, M. F., & Donnino, M. W. (2018). 2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation, 138(23), e740-e749. https://doi.org/10.1161/CIR.0000000000000613

2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. / Panchal, Ashish R.; Berg, Katherine M.; Kudenchuk, Peter J. et al.
In: Circulation, Vol. 138, No. 23, 04.12.2018, p. e740-e749.

Research output: Contribution to journal › Article › peer-review

Panchal, AR, Berg, KM, Kudenchuk, PJ, Del Rios, M, Hirsch, KG, Link, MS, Kurz, MC, Chan, PS, Cabañas, JG, Morley, PT, Hazinski, MF & Donnino, MW 2018, '2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care', Circulation, vol. 138, no. 23, pp. e740-e749. https://doi.org/10.1161/CIR.0000000000000613

Panchal AR, Berg KM, Kudenchuk PJ, Del Rios M, Hirsch KG, Link MS et al. 2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2018 Dec 4;138(23):e740-e749. doi: 10.1161/CIR.0000000000000613

Panchal, Ashish R. ; Berg, Katherine M. ; Kudenchuk, Peter J. et al. / 2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest : An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. In: Circulation. 2018 ; Vol. 138, No. 23. pp. e740-e749.

@article{81aadaaaa52f43cb9167e370a66d72c5,

title = "2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care",

abstract = "Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.",

keywords = "advanced cardiac life support, adult, AHA Scientific Statements, anti-arrhythmia agents, cardiopulmonary resuscitation, heart arrest, tachycardia, ventricular, ventricular fibrillation",

author = "Panchal, {Ashish R.} and Berg, {Katherine M.} and Kudenchuk, {Peter J.} and {Del Rios}, Marina and Hirsch, {Karen G.} and Link, {Mark S.} and Kurz, {Michael C.} and Chan, {Paul S.} and Caba{\~n}as, {Jos{\'e} G.} and Morley, {Peter T.} and Hazinski, {Mary Fran} and Donnino, {Michael W.}",

year = "2018",

month = dec,

day = "4",

doi = "10.1161/CIR.0000000000000613",

language = "English (US)",

volume = "138",

pages = "e740--e749",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "23",

}

TY - JOUR

T1 - 2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest

T2 - An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

AU - Panchal, Ashish R.

AU - Berg, Katherine M.

AU - Kudenchuk, Peter J.

AU - Del Rios, Marina

AU - Hirsch, Karen G.

AU - Link, Mark S.

AU - Kurz, Michael C.

AU - Chan, Paul S.

AU - Cabañas, José G.

AU - Morley, Peter T.

AU - Hazinski, Mary Fran

AU - Donnino, Michael W.

PY - 2018/12/4

Y1 - 2018/12/4

N2 - Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.

AB - Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.

KW - advanced cardiac life support, adult

KW - AHA Scientific Statements

KW - anti-arrhythmia agents

KW - cardiopulmonary resuscitation

KW - heart arrest

KW - tachycardia, ventricular

KW - ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=85058077460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058077460&partnerID=8YFLogxK

U2 - 10.1161/CIR.0000000000000613

DO - 10.1161/CIR.0000000000000613

M3 - Article

C2 - 30571262

SN - 0009-7322

VL - 138

SP - e740-e749

JO - Circulation

JF - Circulation

IS - 23

ER -

2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this